PL.05: Plenary lecture
|
| |
 |
PL.05.01: Francine M. Benes - USA |
Role of GABA neurons in schizophrenia |
E.06: Educational update session: Diagnosis and treatment of the new obsessive compulsive and related disorders
|
 |
|
E.06.01: Dan J. Stein - South Africa |
Obsessive-compulsive and related disorders in DSM-5 and ICD-11: diagnostic issues |
E.07: Educational update session: Pharmacology-based nomenclature: a joint ECNP, CINP, ACNP and AsCNP Task Force
|
| |
|
E.07.03: Guy Goodwin - United Kingdom |
From mood stabilisers to channel blockers |
| |
|
E.07.04: Pierre Blier - Canada |
The new classification of medications exerting antidepressant action |
S.21: Symposium: TNM symposium – Beyond blue: new opportunities for European networks in bipolar disorder
|
| |
|
S.21.04: Guy Goodwin - United Kingdom |
The treatment questions |
S.22: Symposium: TNM symposium – Large-scale European neuroimaging networks: progress and challenges
|
| |
|
S.22.03: David Edwards - United Kingdom |
Developing human connectome project |
S.23: Symposium: Treatment options with GABA-B compounds
|
| |
|
S.23.01: Olivia O'Leary - Ireland |
GABAB1 receptor subunit isoforms differentially modulate resilience to stress |
| |
|
S.23.03: Giancarlo Colombo - Italy |
Anti-alcohol properties of the positive allosteric modulators of the GABAB receptor |
| |
|
S.23.04: Michel Reynaud - France |
Baclofen saga: from myth to evidence |
S.24: Symposium: Inflammation and microglia in psychiatric disorders
|
| |
|
S.24.03: Bartholomeus Haarman - The Netherlands |
New: Neuroinflammation in bipolar disorder - A [11C]-(R)-PK11195 PET study |
| |
|
S.24.04: Pelle de Koning - The Netherlands |
Effect of deep brain stimulation on microglia |
S.25: Symposium: Biological predictors of psychotherapy outcome
|
| |
|
S.25.01: Andreas Reif - Germany |
Mechanisms of fear: the role of MAOA and 5-HT1A |
| |
|
S.25.03: Ulrike Lueken - Germany |
Neuroimaging effects of CBT on fear conditioning in panic disorder |
| |
|
S.25.04: Mark Pollack - USA |
Neuroimaging predictors of treatment response in social phobia |
S.26: Symposium: Cognitive impairment in Parkinson’s disease: role of molecular brain imaging
|
| |
|
S.26.01: Irene Litvan - USA |
The concept of mild cognitive impairment in Parkinson’s disease |
| |
|
S.26.02: Flavio Nobili - Italy |
Disturbed brain metabolism and neurotransmitters in Parkinson's disease with mild cognitive impairment |
| |
|
S.26.04: Caroline Williams-Gray - United Kingdom |
Treatment of cognitive impairment in Parkinson's disease |
S.27: Symposium: New treatment options for sleep disorders
|
| |
|
S.27.01: Gabriella Gobbi - Canada |
Novel selective melatonin MT2 receptor agonist in the treatment of insomnia |
S.28: Symposium: Neuropeptides, obesity and addiction
|
| |
|
S.28.01: Suzanne L. Dickson - Sweden |
The role of the central ghrelin system in reward |
| |
|
S.28.03: Susanne la Fleur - The Netherlands |
Reward and obesity: the role of neuropeptide Y and leptin |
| |
|
S.28.04: Matthew Hayes - USA |
GLP-1 influence on food reward |
CD.05: Career development session:
Jobs in industry versus academia |
| |
|
Thomas Steckler - Belgium |
|
CD.06: Career development session:
How to make a winning poster |
| |
|
Martien Kas - The Netherlands |
|
